Hypercoagulability in centenarians : the paradox of successful aging by D. Mari et al.
Hypercoagulability  in  Centenarians: The Paradox  of  Successful  Aging 
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With advancing age,  an increasing  number of healthy indi- 
viduals  have laboratory signs of heightened coagulation en- 
zyme activity. Such biochemical hypercoagulability might 
be the basis of either the increased thrombotic tendency 
occurring with age or  a  harmless manifestation of this pro- 
cess. To see whether these alterations are  also  present in 
the very elderly who had  aged  successfully, 25 healthy cente- 
narians were studied and results of coagulation and fibri- 
nolysis measurements were compared with those obtained 
in two control groups of healthy adults, 25 ranging in age 
from 18 to 50 years and 25 from 51 to 69 years.  Older controls 
had, in general, slightly higher values of several coagulation 
and fibrinolysis measurements than younger controls. Cen- 
tenarians had striking signs  of heightened coagulation en- 
zyme activity, as  assessed directly by measuring activated 
factor VI1 in plasma (P < .01, compared with either control 
HE PROCESS  OF aging in humans is accompanied by 
modifications of the blood coagulation system. It is 
well established that the plasma concentrations of some co- 
agulation factors (such as factor VII, factor VIII, and fibrin- 
ogen) increase progressively with age.'" However, these pro- 
coagulant proteins are normally present in plasma in such a 
large excess that the pathophysiologic significance of the 
relatively modest increases that occur with aging is uncer- 
tain. Using sensitive immunoassays for markers of coagula- 
tion enzyme activation, Bauer et a14" showed that  with age 
advancing from 42 to 80 years, an increasing number of 
healthy men developed a laboratory picture of enhanced ac- 
tivity of coagulation enzymes, expressed indirectly by high 
plasma levels of the activation peptides that are cleaved from 
prothrombin, factor IX, and factor X when these zymogens 
are converted into the corresponding active enzymes."6 
Because thrombotic disease increases with age, biochemi- 
cal hypercoagulability in the elderly might be the basis for 
their increased thrombotic tendency. On the other hand, the 
phenomenon may simply be a harmless manifestation of the 
aging process. We attempted to evaluate these possibilities 
by studying coagulation and fibrinolysis in a group of healthy 
centenarians. Centenarians are an important natural model 
of successful aging and  may help to identify crucial mecha- 
nisms for the maintenance of homeostasis in  body systems. 
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group) or indirectly by measuring the plasma  levels  of the 
activation peptides of prothrombin, factor IX, factor X, and 
thrombin-antithrombin complexes (all P< .001). Heightened 
coagulation enzyme activity was accompanied by signs of 
enhanced formation of fibrin (high fibrinopeptide A, P< .001) 
and  secondary hyperfibrinolysis (high D-dimer  and plasmin- 
antiplasmin complex, P < .001). Plasma concentrations of 
fibrinogen and factor Vlll were higher than in controls, 
whereas other coagulation factors were not elevated. In con- 
clusion, this study shows the very elderly do not escape the 
state of hypercoagulability associated with aging, but  that 
this phenomenon is compatible with health and longevity. 
Hence, high plasma levels of the coagulation activation 
markers in older populations do not necessarily mirror a 
high risk of arterial or  venous thrombosis. 
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For instance, the study of centenarians has helped to define 
the pathophysiologic relevance of autoimmunity during the 
aging process, as these individuals have much lower levels 
of organ-specific autoantibodies than younger individuals.' 
We  reasoned  that  finding laboratory signs of hypercoagula- 
bility  in centenarians would favor the view that these signs 
are a manifestation of the natural aging process. On the other 
hand, absence of the abnormalities present in noncentenarian 
elderly individuals would indicate that there has  been a selec- 
tion process, leaving those individuals who aged without 
signs of hypercoagulability alive and healthy. 
MATERIALS AND METHODS 
Subjects. A total of 75 individuals were studied: 25 (the cases) 
were more than 1 0 0  years old, and 50 (the controls) were less than 
100 years old. Approval for these studies was obtained from the 
Institutional Review  Board  of  the University of  Milan  and informed 
consent was obtained according to  the Declaration of Helsinki. 
Centenarians. Centenarians (age range, 100 to 102 years, 9 men 
and 16 women) were ambulatory, self-sufficient, and lived in their 
homes. Followed at the Institute of Internal Medicine, they were 
chosen on  the  basis of the strict criteria set by the Senieur protocol.' 
This protocol establishes admission criteria for gerontologic studies 
based on clinical history, physical examination, and laboratory data 
and sets limits for pharmacologic interferences. By setting strict 
criteria for choosing centenarians, our aim was to exclude endoge- 
nous and exogenous influences on the coagulation system and to 
standardize the population under study. Causes for exclusions were 
smoking, alcohol abuse, intake of drugs affecting hemostasis, and 
chronic disorders such as infection, inflammation, malignancy, car- 
diac insufficiency, dementia, diabetes, cataracts, renal, and liver dis- 
ease. An electrocardiogram, hemocytometry, and urinalysis were 
obtained in all centenarians and erythrocyte sedimentation rate and 
plasma concentrations of glucose, sodium, potassium, albumin, alka- 
line phosphatase, alanine and aspartate aminotransferase, urea, and 
creatinine were measured. Centenarians with values outside the 2.5 
and 97.5 percentile of  the reference values were excluded. 
Controls. Controls (n = 50, 20 men and 30 women) were blood 
donors or hospital staff members, and were chosen to make up two 
groups of equal size: younger controls, ages 18 to 50 years and older 
controls, ages 51 to 69 years. On the basis of history and physical 
examination, none of  them  had  any  of  the conditions taken as causes 
of disqualification for the group of healthy centenarians. The same 
hematochemical parameters were evaluated in the control popula- 
tion. 
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Blood sampling and processing. Venous blood was obtained 
between 8:OO and 1000 AM from the antecubital veins by two- 
syringe techniques using 19-gauge needles. Blood samples for factor 
IX and X peptide assays were drawn into plastic syringes preloaded 
with the following anticoagulant: 38 mmol/L citric acid, 75 mmoU 
L sodium citrate, 136 mmol/L dextrose, 6 mmom EDTA, 6 mmoU 
L adenosine, and 25 U/mL heparin. The ratio of anticoagulant to 
blood was 0.2:l.O (voVvol). For the prothrombin fragment assay, an 
anticoagulant containing a synthetic thrombin inhibitor, EDTA  and 
aprotinin was purchased from Byk-Sangtec (Dietzenbach, Germany) 
and the ratio of anticoagulant to blood was 0.1:0.9 (voUvol). For 
fibrinopeptide A assay, an anticoagulant provided by the manufac- 
turer of the assay kit (see below) and containing unspecified amounts 
of heparin and aprotinin was used (anticoagulanthlood ratio: 
0.2:l.O). All of the remaining coagulation and fibrinolysis assays 
were carried out on blood collected in sodium citrate at a final 
concentration of 3.8% (wthol). All plasma specimens were centri- 
fuged at 4°C for 20 minutes at 2,OOOg and stored at -80°C until 
assayed within 2 to 3 months. Assays of the factor IX and X activa- 
tion peptides and the prothrombin fragment 1+2 were carried out 
in Boston, MA. All other assays were done in Milan, Italy. 
Assays of coagulation activation markers. Activated factor VI1 
(factor VIIa), the enzymatic form of factor VII, was measured by a 
one-stage, prothrombin time-based assay using a truncated soluble 
form of recombinant tissue factor (kindly supplied by  Dr Y. Nemer- 
son, Mount Sinai Hospital Medical School, New York, NY) that, 
upon relipidation, reacts with factor VIIa but not with one-chain 
factor VIL9 The factor X activation peptide is cleaved from factor 
X when this zymogen is activated by factor VIIa-tissue factor com- 
plex or by activated factor IX-activated factor VIII-activated surface 
complex; the factor IX activation peptide is cleaved from factor IX 
when this zymogen is activated by factor VIIa-tissue factor or acti- 
vated factor XI. Both peptides were then measured by double-anti- 
body radioimmunoassay (RIA) in plasma extracted before assay to 
eliminate nonspecific interference from other plasma Pro- 
thrombin fragment 1 +2 is a measure of the cleavage of prothrombin 
by activated factor X (factor Xa) being released from the aminoter- 
mina1 portion of the molecule during its conversion to thrombin. It 
was measured in plasma by a previously described double-antibody 
RIA.'" Thrombin-antithrombin complex, a measure of thrombin gen- 
eration and neutralization by antithrombin, was assayed by enzyme- 
linked immunosorbent assay (ELISA) using a kit from Behringwerke 
(Marburg, Germany). Fibrinopeptide A is a measure of the formation 
of  fibrin being released from the a-chain of fibrinogen when throm- 
bin converts fibrinogen to fibrin. It was assayed by ELISA in plasma 
extracted twice with bentonite to remove fibrinogen, using a kit from 
Boehringer Biochemia (Mannheim, Germany). 
Assays of coagulation factors. The coagulant activities of factors 
11, VII, VIII, IX, and X were measured by standard one-stage func- 
tional assays using congenitally deficient plasmas containing less 
than one percent coagulant activities. Values were expressed in per- 
cent of pooled normal plasma. Plasma fibrinogen was measured by 
a fibrin polymerization assay (Boehringer Biochemia). 
Assays of anticoagulant proteins. Antithrombin was assayed by 
an amidolytic method using the chromogenic substrate S-2238 as- 
sembled into a kit by Chromogenix (Molndal, Sweden). Protein C 
was determined by an amidolytic method (Chromogenix) and total 
protein S antigen by ELISA (Diagnostica Stago, Asnieres, France), 
according to the recommendations of  the manufacturers of the corre- 
sponding assay kits. Tissue factor pathway inhibitor activity was 
measured in a two-stage chromogenic assay, according to the method 
of Sandset et al." 
FibrinoZysis assays. Plasminogen and a,-antiplasmin were as- 
sayed by an amidolytic method using commercial kits (Chromo- 
genix). D-dimer and plasmin-antiplasmin complex were measured 
by ELISA (Dimertest, Agen Biomedical, Brisbane, Australia; Beh- 
ringwerke, Marburg, Germany). Plasminogen activator inhibitor type 
1 activity was measured by a chromogenic method (Biopool, Umea, 
Sweden). 
Statistical analysis. The values obtained in controls and cente- 
narians were analyzed after transformation into logarithms, but for 
descriptive purposes are given as geometric means and 95% confi- 
dence intervals. Comparisons between the groups were made by 
analysis of variance and between-group differences assessed with 
the Scheffe test. Because multiple comparisons were done in the 
analysis, the level of statistical significance was set  at less than .01. 
Correlation coefficients were calculated from log-transformed data 
by linear regression analysis. 
RESULTS 
Table 1 summarizes the overall results (geometric means 
and 95% confidence intervals) of the measurements of coag- 
ulation and fibrinolysis obtained in centenarians and in the 
two control populations of younger and older healthy adults. 
The reference values for each measurement are also pro- 
vided, reflecting the ranges established in the two labora- 
tories that had tested larger groups of healthy individuals at 
the time of the standardization of the assays. 
Coagulation  activation  markers. The older controls 
tended to have higher values than younger controls for all 
of the measurements, but no difference reached statistical 
significance (P > .01). The plasma concentrations of factor 
VIIa were significantly elevated in the plasma of centenari- 
ans (P < .01) (Table l), although there was overlap with 
the values measured in both younger and older controls (Fig 
1). The plasma levels of the factor X and factor IX activation 
peptides were very elevated in centenarians ( P  < .001) (Ta- 
ble l), with little overlap with the control groups, particularly 
for the factor X activation peptide (Fig 1). The prothrombin 
fragment 1 +2, thrombin-antithrombin complex and fibrino- 
peptide A were also very elevated in centenarians ( P  < .001) 
(Table 1 and Fig 2). 
There were positive correlations between the levels of the 
factor IX and factor X activation peptides and between either 
of them and factor VIIa levels (Table 2). The levels of factor 
VIIa and of the factor X activation peptide were correlated 
with those of the prothrombin fragment 1 +2 (Table 2). There 
were no significant correlations between the plasma concen- 
trations of activation markers and creatinine, blood  urea,  and 
results of liver function tests, such as albumin and amino- 
transferases (not shown). 
Coagulation factors. Plasma levels of fibrinogen, factor 
VII, and factor VI1 tended to be higher in older controls, 
but the differences from younger controls were statistically 
significant only for factor VI11 (Table 1). Fibrinogen and 
factor VI11 were significantly higher in centenarians than in 
either control group (Table 1). The concentrations of factor I1 
(prothrombin), factor IX, and factor X were not  significantly 
different or were lower than those found in the control groups 
(Table 1). 
Anticoagulant proteins. In centenarians, the two compo- 
nents of the activated protein C anticoagulant pathway that 
are measurable in plasma (protein C and protein S) did not 
differ from either control group (Table 1). The tissue factor 
pathway inhibitor, the main regulator of the tissue factor/ 
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Table 1. Geometric  Means (95% Confidence Intervalsl of Hamostasis MoawMments in Youngw Controls, Oldw Controls,  and  Centenarians 
PValues 
Younger Controls Older Controls Centenarians 
Measurements (11 (21 (31 1 v 2  1 v 3  2 v 3  Reference Values 
Coagulation enzymes and 
activation peptides 
Factor Vila (ng/mL) 
Factor IX activation peptide 
Factor X activation peptide 
Prothrombin fragment 1+2 
Thrombin/antithrombin 
(pmol/L) 
(pmol/L) 
(nmol/L) 
complex (ng/mL) 
Fibrinopeptide A (nmol/L) 
Coagulation factors 
Fibrinogen (mg/dL) 
Factor VI11 (%) 
Prothrombin (%) 
Factor VI1 (%) 
Factor IX I%) 
Factor X (%) 
Anticoagulant proteins 
Antithrombin (%) 
Protein C (%) 
Tissue factor pathway inhibitor 
Protein S (%l 
Fibrinolysis measurements 
Plasminogen (%) 
Plasminogen activator 
a2-antiplasmin ( 4 6 )  
Plasmin-antiplasmin complex 
D-dimer  (ng/mL) 
(96) 
inhibitor type I IIUlmL) 
(ng/mL) 
3.18  (2.76-3.64) 
164  (144-185) 
86  (81-92) 
0.56  (0.49-0.64) 
2.0 (1.6-2.4) 
0.89  (0.74-1.06) 
263  (244-284) 
97  (90-105) 
104  (99-108) 
99  (93-105) 
96  (93-100) 
103  (97-108) 
98  (95-101) 
87  (82-92) 
95  (89-102) 
106  (98-113) 
97  (93-102) 
3.0  (1.4-6.7) 
90  (87-93) 
295  (262-332) 
29  (24-36) 
3.24  (2.86-3.67) 
207  (187-229) 
99  (85-115) 
0.69  (0.61-0.78) 
2.4  (2.0-2.8) 
1.22 ( 1 .OO-1.50) 
312  (287-338) 
134  (119-151) 
98  (95-102) 
110  (104-116) 
104  (95-113) 
96  (91-102) 
97  (91-104) 
88  (83-93) 
110  (102-118) 
115  (100-132) 
93  (89-97) 
3.4  (2.3-4.9) 
94  (90-98) 
359  (316-408) 
50  (39-64) 
4.46  (3.91-5.06) 
391  (351-435) 
248 (226-272) 
1.15  (0.93-1.43) 
5.9  (4.6-7.6) 
1.99  (1.72-2.31) 
347  (313-385) 
165  (147-185) 
88  (82-93) 
1 1 1  (103-119) 
107  (98-1  17) 
83  (77-89) 
91  (85-98) 
90  (83-98) 
109  (100-118) 
109  (97-123) 
98  (94-102) 
3.4  (1.9-6.0) 
90  (85-95) 
828  (738-927) 
323  (255-408) 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
< ,001 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
,004 
.002 
<.001 
< m 1  
<.001 
<.001 
<.001 
4.001 
< .001 
<.001 
NS 
NS 
<.001 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
<.001 
< ,001 
,004 
<.001 
< . m 1  
<.001 
< B O 1  
1.001 
.005 
.005 
,005 
NS 
NS 
.003 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
<.001 
<.001 
2.3-5.9 
131-284 
39-1  12 
0.40-1.30 
1 .O-4.0 
0.5-2.0 
193-365 
53-1  52 
71-125 
70-133 
69-125 
72-119 
80-  120 
67-1  29 
61-140 
65-1  29 
70-  133 
2-14 
71-125 
80-280 
2.0-14.0 
Abbreviation: NS, not significant. 
factor VIIa pathway, and antithrombin, the main inhibitor 
of thrombin, were also not different (Table l). 
Fibrinolysis measurements. Plasminogen, the key zymo- 
gen of the fibrinolytic system, and the two principal inhibi- 
tors of the system (plasminogen activator inhibitor type 1 
and a2-antiplasmin) were not elevated in centenarians (Table 
1). However, centenarians had clear signs of hyperfibrino- 
lysis, expressed by  very high levels of D-dimer (an index of 
plasmin activity on cross-linked fibrin) and plasmin-antiplas- 
min complex (an index of plasmin formation and neutraliza- 
tion) (both P < .001 compared with either control group) 
(Table 1 and Fig 3). The latter two measurements were posi- 
tively correlated with each other and with the indexes of 
thrombin generation and activity (Table 2). 
DISCUSSION 
A large proportion of centenarians had laboratory signs of 
coagulation activation, expressed by  high levels of enzymes, 
activation peptides, and enzyme-inhibitor complexes. F’roco- 
agulant proteins, such as fibrinogen and factor VIII, that 
epidemiologic studies have shown to be useful predictors of 
cardiovascular disease in middle-aged were 
also elevated in centenarians. Yet, these individuals were 
healthy and their striking biochemical abnormalities were 
not associated with  a disease state, even though the presence 
of asymptomatic atherosclerosis cannot be ruled out. 
Elevated plasma concentrations of markers of coagulation 
activation might be caused by increased production or by 
decreased clearance. In their study of age-related changes in 
these markers, Bauer et a14 directly measured the half-life 
of the prothrombin activation fragment after its infusion into 
10 elderly men and showed that the clearance of this moiety 
was normal. Because these studies could not be performed in 
our centenarians, decreased clearance of activation markers 
cannot be directly excluded. On the other hand, centenarians 
had normal liver and kidney function tests, so that a mecha- 
nism of decreased clearance due to liver or renal insuffi- 
ciency does not appear to be a likely explanation for the 
high plasma concentrations of these markers. 
The most striking finding of this study was that centenari- 
ans had very high plasma concentrations of the activation 
peptide of factor X, the coagulation zymogen placed at the 
junction of the extrinsic and intrinsic pathways, which indi- 
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Fig 1. Plasma concentrations  of  activated  factor VII, factor X acti- 
vation peptide, and  factor IX activation  peptide in 25 centenarians 
(cen, 0). 25 controls aged 51 to  69 years Icon 2, O), and 25 controls 
aged 18 t o  50 years (con 1.0). The solid  horizontal  lines  denote  the 
geometric  mean values of each parameter in each group. 
cate excessive generation of factor Xa under in vivo condi- 
tions. The levels of factor X activation peptide were as high 
as those found in patients with disseminated intravascular 
coagulation.5 In normal individuals, when there is no patho- 
logic trigger of blood coagulation and  no  need for enhanced 
hemostasis, generation of factor Xa occurs predominantly 
through  the enzymatic action of the factor Vlla-tissue factor 
complex, which activates factor X.I4.l5 The factor Vlla-tissue 
factor pathway  is also largely responsible for the activation 
of factor IX.I4 In centenarians, the  plasma levels of the factor 
IX activation peptide were  very high, even  higher  than  those 
found by Bauer et al," using the same assay method, in 
elderly individuals aged 71 to 80 years (mean values: 391 
l" 
6 -  
4 -  
0 
0 
0 
0 
0 
0 
0 
V 
2o 1 
15 - 
10 - 
0 
0 
0 
000 
0 
0 
5 
0 
con 1 con 2 cen 
Fig 2. Plasma concentrations of  prothrombin  fragment 1 + 2, fi- 
brinopeptide A, and thrombin-antithrombin complex. See Fig 1 for 
symbols. 
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Table 2. Correlation Coefficients (r values) Between  Markers of Coagulation and Fibrinolysis Enzyme Activity in Centenarians 
FXP  FlXP  F1+2 FPA TAT w n  PAP 
Factor Vlla (FVlla) 0.551~ 0.45t 0.60' 0.35 0.38 0.29 0.35 
Factor X activation peptide  (FXP) 0.62*  0.66*  0.44t  0.52*  0.38  0.45t 
Factor IX activation peptide (FIXP) 0.34 0.41 t 0.35  0.29  0.29 
Prothrombin fragment 1 +2 (F1 +2)  0.47t 0.51* 0.51' 0.46t 
Fibrinopeptide A (FPA) 0.58* 0.47t 0.34 
Thrombin-antithrombin  complex  (TAT) 0.46t  0.44t 
D-dimer  (D-D) 0.54* 
Plasmin-antiplasmin complex (PAP) 
P < .01. 
t P < .05. * P < ,001. 
pmol/L in  centenarians v 274 in 7 1 - to 80-year-old  individu- 
als). In centenarians,  there was a  positive  correlation  between 
the elevated concentrations of factor X activation peptide 
and those  of the  factor IX  activation  peptide. suggesting that 
they are associated phenomena. Therefore. it  is likely that 
both are the  results  of  the  heightened enzymatic activity  of 
factor Vlla-tissue factor complex. as in physiologic condi- 
tions. However, the elevations of factor  Vlla  concentrations 
were  less marked than those of the two activation peptides 
and  the  correlations weaker.  Because  factor Vlla has  a high 
affinity for its cofactor tissue factor expressed on cell sur- 
faces.'" the measurement of the levels of this enzyme in 
plasma may reflect only a small portion of the enhanced 
activity  of  the  factor  VIla-tissue  factor  complex  exerted 
mainly  at the level of the  cell  surfaces. 
Consistent with the  findings of heightened  factor X activa- 
tion. the  late  reactions  of  blood  coagulation  were also acti- 
vated in centenarians.  Prothrombin  fragment 1 +2, the  prod- 
uct of prothrombin cleavage by factor Xa. was markedly 
fragment in centenarians with those found by Bauer et al' 
in younger individuals  aged 71 to 80  years because  the  cur- 
rent assay  uses  a  different  antibody  that  gives lower values 
in healthy individuals. There were also signs of enhanced 
thrombin  generation (high thrombin-antithrombin com- 
plexes), fibrin formation (high fibrinopeptide A). and  hyper- 
fibrinolysis (high D-dimer and plasmin-antiplasmin levels). 
which  were  probably  the  expression of excessive fibrin for- 
mation and dissolution with values similar to those usually 
tion. 
vation of the coagulation system found in  centenarians. we 
surmise that in  these  individuals  there is an enhanced  expres- 
sion and availability of tissue factor, which would. in turn. 
expressed in the intact vasculature.'" but perhaps changes 
associated with aging can  modify the physiologic  situation. 
induce the expression  of  tissue  factor. and thereby  accelerate 
the  factor Vlldtissue factor  pathway. The natural regulatory 
mechanisms may thus be overwhelmed.  leading to a  state  of 
changes can  only be speculative  at  the  moment. Tissue factor 
expression  can be induced by a  variety of agonists.  such as 
endotoxins, inflammatory  cytokines.  activated  lymphocytes. 
growth factors, and oxidized low-density lipoproteins.'" I t  
has been shown that in centenarians there is a marked in- 
crease in the number of  circulating  activated T lymphocytes 
(CD3 and  HLA-DR  positive),"  which  may interact with 
macrophages-monocytes andlor endothelial cells and uDree- 
1000 elevated. It is impossible to compare the high values of this 
800 
600 
400 
200 found in patients with disseminated  intravascular  coagul - 
0 In an attempt to explain  mechanistically the  dramatic  acti- 
2000 - augment factor VI1 activation. Tissue factor is usually not 
1500 - 
8 
8 
1000 - 8 marked  coagulation  system  activati . The nature  of  these 
0 
0 
con 1 con2 cen 
Fig 3. Plasma concentrations of D-dimer and plasmin-antiplasmin ulate the expression of tissue factor in these cells.'x This 
. -  
complex. See  Fig l for symbols. mechanism  for enhanced  tissue  factor  expression  has been 
HYPERCOAGULABILITY IN CENTENARIANS 31 49 
documented to cause the hypercoagulable state associated 
with unstable angina.’’ 
Despite high coagulation enzyme activity leading to dis- 
crete fibrin formation and secondary hyperfibrinolysis, cente- 
narians were healthy and had no current or past thrombotic 
episodes. In general, the clinical significance and predictive 
value of biochemical markers of hypercoagulability remain 
to be established and are currently being evaluated in pro- 
spective studies carried out in middle-aged individuals. Be- 
cause this investigation shows that marked alterations of 
these markers are compatible with health and longevity, 
plasma levels of coagulation activation markers in a study 
population must always be interpreted in concert with an 
appropriate control group, and high levels do not necessarily 
mirror a high risk of arterial or venous thrombosis. The same 
reasoning can be applied to procoagulant proteins, such as 
factor VI11 and fibrinogen, which are predictors of cardiovas- 
cular disease in middle-aged individuals and yet are elevated 
in healthy centenarians. 
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